New biologic drug shows promise for eczema in early trial

NCT ID NCT05277571

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-phase trial tested a new biologic drug called UCB1381 in 109 people, first in healthy volunteers and then in those with moderate to severe atopic dermatitis (eczema). The goal was to check safety and see if it improves eczema symptoms. Participants received either the drug or a placebo, and researchers tracked side effects and skin improvement over 12 to 22 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UCB1381 (a biologic drug given by injection or IV)
What this could lead to: If successful, this could point toward a new treatment option for people with moderate to severe eczema.
What could go wrong: This is an early phase 1/2A trial with only 109 participants, so results may not confirm effectiveness or safety for wider use. Side effects are possible, and the drug may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Up0110 101

Glendale, California, 91206, United States
Up0110 102

St. Petersburg, Florida, 33705, United States
Up0110 104

Oklahoma City, Oklahoma, 73170, United States
Up0110 106

Ocala, Florida, 34471, United States
Up0110 107

New York, New York, 10029, United States
Up0110 108

Clearwater, Florida, 33765, United States
Up0110 109

Miami Lakes, Florida, 33014, United States
Up0110 111

College Park, Georgia, 30349, United States
Up0110 114

Minneapolis, Minnesota, 55455, United States
Up0110 116

Los Angeles, California, 90045, United States
Up0110 119

Philadelphia, Pennsylvania, 19103, United States
Up0110 121

Northridge, California, 91324, United States
Up0110 124

Winston-Salem, North Carolina, 27103, United States
Up0110 125

Beverly Hills, California, 90212, United States
Up0110 126

Tustin, California, 92780, United States
Up0110 127

Valencia, California, 91355, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.